An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion

F Barkhof, M Daams, P Scheltens… - American Journal …, 2013 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Immune therapy against amyloid-β appears to be a
promising target in Alzheimer disease. However, a dose-related risk for ARIA on FLAIR …

Validation of an MRI rating scale for amyloid‐related imaging abnormalities

A Bechten, MP Wattjes, DD Purcell… - Journal of …, 2017 - Wiley Online Library
ABSTRACT INTRODUCTION Immunotherapeutic agents against amyloid beta (Aβ) are
associated with adverse events, including amyloid‐related imaging abnormalities with …

MR imaging features of amyloid-related imaging abnormalities

J Barakos, R Sperling, S Salloway… - American Journal …, 2013 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: AD is one of the few leading causes of death without a
disease-modifying drug; however, hopeful agents are in various phases of development. MR …

Amyloid-related imaging abnormalities: An update

M Roytman, F Mashriqi, K Al-Tawil… - American Journal of …, 2023 - Am Roentgen Ray Soc
Please see the Editorial Comment by Can Ozutemiz discussing this article. Amyloid-related
imaging abnormalities (ARIA) is a term introduced in 2010 to encompass a spectrum of MRI …

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

R Sperling, S Salloway, DJ Brooks, D Tampieri… - The Lancet …, 2012 - thelancet.com
Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients
with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody …

Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies

HR Brashear, N Ketter, J Bogert, J Di… - Journal of …, 2018 - content.iospress.com
Background: Amyloid-related imaging abnormalities with effusion or edema (ARIA-E)
reported in patients with mild-to-moderate Alzheimer's disease in bapineuzumab phase III …

[HTML][HTML] Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy

J Barakos, D Purcell, J Suhy, S Chalkias… - The Journal of …, 2022 - Springer
Amyloid-related imaging abnormalities (ARIA) are adverse events reported in Alzheimer's
disease trials of anti-amyloid beta (Aβ) therapies. This review summarizes the existing …

Incidence of amyloid-related imaging abnormalities in patients with Alzheimer disease treated with anti–β-amyloid immunotherapy: a meta-analysis

SY Jeong, CH Suh, WH Shim, JS Lim, JH Lee, SJ Kim - Neurology, 2022 - AAN Enterprises
Background and Objectives To assess the incidence of amyloid-related imaging
abnormalities (ARIA) in clinical trials of anti–β-amyloid (Aβ) immunotherapy and compare …

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics

H Hampel, A Elhage, M Cho, LG Apostolova… - Brain, 2023 - academic.oup.com
Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in
the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show …

Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer's disease patients

N Ketter, HR Brashear, J Bogert, J Di… - Journal of …, 2017 - content.iospress.com
Background: Amyloid-related imaging abnormalities (ARIA) consist of ARIA-E (with effusion
or edema) and ARIA-H (hemosiderin deposits [HDs]). Objectives: To address accurate …